Janssen Presents P-Ib/II Study (CHRYSALIS-2) Results of Rybrevant (amivantamab-vmjw) + Lazertinib for EGFR-Mutated Advanced NSCLC at IASLC 2023 WCLC
Shots:
- The P-Ib/II study cohort evaluating Rybrevant (a bispecific Ab targeting EGFR & MET) + lazertinib (EGFR TKI) and Pt-based CT in 460 patients with r/r NSCLC & EGFR mutations
- The results showed that patients treated with the combination therapy achieved an ORR (50%) with 11 out of 20 patients remaining on treatment, m-DoR (not reached) after a median follow-up of 13.1mos., m-PFS was 14mos., 8 out of 10 responders had a response duration of 6mos., 5 were treated beyond progression with a median incremental treatment duration of 4.2mos. & showed durable PFS
- Rybrevant received accelerated approval in the US for adult patients with LA or metastatic NSCLC with EGFR exon 20 insertion mutations & received approval from health authorities in the EU & other markets globally
Ref: PRNewswire | Image: Janssen
Related News:- Janssen Reports P-III Study (MARIPOSA-2) Results of Rybrevant (amivantamab-vmjw) for EGFR-Mutated Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
